Concepts (92)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Maltose | 1 | 2021 | 34 | 0.790 |
Why?
|
| Hypophosphatemia | 1 | 2021 | 85 | 0.730 |
Why?
|
| Hyperoxaluria | 1 | 2019 | 32 | 0.690 |
Why?
|
| Ferric Compounds | 1 | 2021 | 374 | 0.670 |
Why?
|
| Phosphates | 1 | 2021 | 786 | 0.600 |
Why?
|
| Interleukin-2 | 1 | 2024 | 1904 | 0.580 |
Why?
|
| Organ Transplantation | 1 | 2024 | 1139 | 0.460 |
Why?
|
| Diabetic Nephropathies | 1 | 2019 | 984 | 0.410 |
Why?
|
| Colitis, Ulcerative | 1 | 2021 | 1912 | 0.330 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 2208 | 0.260 |
Why?
|
| Kidney Transplantation | 3 | 2023 | 4251 | 0.220 |
Why?
|
| Thrombocythemia, Essential | 1 | 2022 | 105 | 0.190 |
Why?
|
| Proteinuria | 1 | 2023 | 658 | 0.180 |
Why?
|
| Primary Myelofibrosis | 1 | 2022 | 215 | 0.180 |
Why?
|
| Oxalates | 1 | 2019 | 105 | 0.170 |
Why?
|
| Aquaporin 2 | 2 | 2016 | 148 | 0.160 |
Why?
|
| Transplantation, Homologous | 2 | 2024 | 4776 | 0.160 |
Why?
|
| Obesity | 1 | 2019 | 12745 | 0.140 |
Why?
|
| Kidney Medulla | 1 | 2016 | 182 | 0.140 |
Why?
|
| Water-Electrolyte Balance | 1 | 2016 | 346 | 0.130 |
Why?
|
| Oxazoles | 1 | 2016 | 189 | 0.130 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2016 | 431 | 0.120 |
Why?
|
| Monitoring, Physiologic | 1 | 2022 | 1738 | 0.120 |
Why?
|
| Graft Survival | 1 | 2024 | 3737 | 0.110 |
Why?
|
| Tacrolimus | 1 | 2016 | 743 | 0.110 |
Why?
|
| Glucosides | 1 | 2016 | 451 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2015 | 640 | 0.100 |
Why?
|
| Deoxycytidine | 1 | 2015 | 826 | 0.100 |
Why?
|
| Fluorouracil | 1 | 2015 | 1619 | 0.090 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 2988 | 0.090 |
Why?
|
| Benzhydryl Compounds | 1 | 2016 | 845 | 0.090 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2016 | 1116 | 0.090 |
Why?
|
| Aortic Coarctation | 1 | 2012 | 281 | 0.090 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 1972 | 0.080 |
Why?
|
| Graft Rejection | 1 | 2022 | 4397 | 0.080 |
Why?
|
| Antibody Formation | 2 | 2023 | 1402 | 0.080 |
Why?
|
| Antibodies, Viral | 3 | 2023 | 3176 | 0.070 |
Why?
|
| Cell Membrane | 1 | 2016 | 3748 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 3523 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 9274 | 0.070 |
Why?
|
| Cerebral Angiography | 1 | 2012 | 1285 | 0.070 |
Why?
|
| Receptor, erbB-2 | 1 | 2015 | 2416 | 0.060 |
Why?
|
| Melanoma | 1 | 2022 | 5510 | 0.060 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2022 | 130 | 0.050 |
Why?
|
| Hydroxyurea | 1 | 2022 | 290 | 0.050 |
Why?
|
| Kidney | 1 | 2016 | 7186 | 0.050 |
Why?
|
| Oximes | 1 | 2022 | 311 | 0.050 |
Why?
|
| Humans | 11 | 2024 | 744343 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2022 | 371 | 0.040 |
Why?
|
| Inflammation | 1 | 2019 | 10638 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 634 | 0.040 |
Why?
|
| Isoantibodies | 1 | 2022 | 679 | 0.040 |
Why?
|
| Brain Ischemia | 1 | 2012 | 3265 | 0.040 |
Why?
|
| Pyridones | 1 | 2022 | 712 | 0.040 |
Why?
|
| Marine Toxins | 1 | 2016 | 24 | 0.040 |
Why?
|
| Glycosuria | 1 | 2016 | 43 | 0.040 |
Why?
|
| Mice | 1 | 2024 | 81183 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2022 | 1607 | 0.030 |
Why?
|
| Imidazoles | 1 | 2022 | 1206 | 0.030 |
Why?
|
| Animals | 3 | 2024 | 168757 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2016 | 8301 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2023 | 1978 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2022 | 2043 | 0.030 |
Why?
|
| Membrane Transport Proteins | 1 | 2016 | 1028 | 0.020 |
Why?
|
| Female | 4 | 2022 | 380194 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 1770 | 0.020 |
Why?
|
| Vaccination | 1 | 2022 | 3278 | 0.020 |
Why?
|
| Stroke | 1 | 2012 | 9981 | 0.020 |
Why?
|
| Adult | 2 | 2021 | 214055 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2022 | 11524 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2023 | 53288 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 20822 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2015 | 3913 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 4933 | 0.020 |
Why?
|
| Mastectomy | 1 | 2015 | 1793 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2016 | 3798 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2016 | 8436 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 6895 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 6538 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2023 | 77449 | 0.010 |
Why?
|
| Aged | 3 | 2022 | 163280 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2016 | 6256 | 0.010 |
Why?
|
| Prognosis | 1 | 2022 | 29063 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 11031 | 0.010 |
Why?
|
| Recurrence | 1 | 2012 | 8340 | 0.010 |
Why?
|
| Rats | 1 | 2016 | 24260 | 0.010 |
Why?
|
| Middle Aged | 3 | 2022 | 213383 | 0.010 |
Why?
|
| Mutation | 1 | 2022 | 29786 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2015 | 63114 | 0.010 |
Why?
|
| Male | 3 | 2022 | 350118 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 57776 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 20129 | 0.010 |
Why?
|
Concepts
(92)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(24)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_